Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Boston Beer Company Inc — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.5 (market cap $31.07B), while Boston Beer Company Inc trades at $176.75 (market cap $1.82B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 17.1× Boston Beer Company Inc's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals.
| GEHC | SAM | |
|---|---|---|
Market Cap | $31.07B | $1.82B |
Volume | 3,443,020 | 202,975 |
Sector | Health | Consumer Staples |
52-Week High | $88.16 | $260.05 |
52-Week Low | $59.48 | $161.08 |
Enterprise Value | $39.53B | $1.59B |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 60 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
SAM trades at $178.14, up 1.74% today, near resistance at $178. The stock shows a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, 2025 revenue held at $1.96B with net income improving to $108M, yet 2026 guidance projects a net loss. The company is expanding its brand portfolio with new products and marketing initiatives to counter volume declines.
Outlook: SAM faces near-term headwinds from projected 2026 losses and competitive pressure, but brand investments and innovation provide growth avenues. Risks include execution challenges and weak consumer demand. The consensus price target of $204.44 implies potential upside, supported by a debt-free balance sheet, but investor sentiment remains cautious amid earnings misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
